NCT06849986: IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
- State
- Under way
- Phase
- Phase 2
- People
- 45 planned
- Started
- 25 Feb 2025
- Primary completion
- 31 Dec 2027
- Arms
- tislelizumab combined with AI
- Results
- None posted
- 25 Feb 2025: Trial started
- 27 Feb 2025: Trial registered